In this Seminar we discuss developments from the past 5 years in the diagnosis,
neurobiology, and treatment of major depressive disorder. For diagnosis, psychiatric and …

The panoply of cognitive, affective, motivational, and social functions that underpin everyday
human experience requires precisely choreographed patterns of interaction between …

Major efforts have been directed at family-based association and case–control studies to
identify the involvement of candidate genes in the major disorders of mental health. What …

Resilience is the ability to cope with critical situations through the use of personal and
socially mediated resources. Since a lack of resilience increases the risk of developing …

Mood disorders are marked by high rates of non-recovery, recurrence, and chronicity, which
are insufficiently addressed by current therapies. Several patho-etiological models have …

Type A monoamine oxidase (MAOA) catabolizes monoamine transmitters, serotonin,
norepinephrine and dopamine, and plays a major role in the onset, progression and therapy …

Increasing evidence supports the involvement of both heritable and environmental risk
factors in major depression (MD) and suicidal behavior (SB). Studies investigating gene …

In the field of pharmacogenetics, we currently have a few markers to guide physicians as to
the best course of therapy for patients. For the most part, these genetic variants are within a …

Emerging evidence from randomized, double-blind, placebo-controlled clinical trials
suggests psychedelic compounds such as 3, 4-methylenedioxymethamphetamine (MDMA) …

Major depressive disorder is a heterogeneous disorder, mostly diagnosed on the basis of
symptomatic criteria alone. It would be of great help when specific biomarkers for various …